论文部分内容阅读
目的观察噻托溴铵联合沙美特罗/丙酸氟替卡松复合剂治疗稳定期慢性阻塞性肺疾病(COPD)的临床效果。方法回顾性分析长葛市人民医院2013年2月—2014年2月期间收治的90例稳定期慢性阻塞性肺疾病患者的临床资料,按照治疗方法的不同分为观察组(45例)和对照组(45例),对照组采用常规+噻托溴铵治疗,观察组采用常规治疗+噻托溴铵联合沙美特罗/丙酸氟替卡松复合剂治疗,观察两组患者的治疗效果。结果观察组总有效率84.4%,对照组总有效率68.9%,两者相比差异有统计学意义(P<0.05),观察组优势明显。结论在常规治疗基础上采用噻托溴铵联合沙美特罗/丙酸氟替卡松复合剂的治疗方案治疗稳定期COPD疗效确切,用药安全方便,不良反应少,值得临床推广应用。
Objective To observe the clinical efficacy of tiotropium combined with salmeterol / fluticasone propionate in the treatment of patients with stable chronic obstructive pulmonary disease (COPD). Methods The clinical data of 90 patients with stable chronic obstructive pulmonary disease (COPD) treated in Changge People’s Hospital from February 2013 to February 2014 were retrospectively analyzed. According to the different treatment methods, the patients were divided into observation group (45 cases) and control group (N = 45). The control group was treated with conventional + tiotropium. The observation group was treated with conventional therapy plus tiotropium combined with salmeterol / fluticasone propionate. The therapeutic effect was observed in both groups. Results The total effective rate was 84.4% in the observation group and 68.9% in the control group, the difference was statistically significant (P <0.05). The observation group had obvious advantages. Conclusion The treatment of stable COPD with tiotropium combined with salmeterol / fluticasone propionate on the basis of conventional treatment is effective, safe and convenient to use, and has few adverse reactions. It is worthy of clinical application.